456 related articles for article (PubMed ID: 29197738)
1. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G
J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738
[TBL] [Abstract][Full Text] [Related]
2. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
Deardorff WJ; Grossberg GT
Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953
[TBL] [Abstract][Full Text] [Related]
3. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2015 Feb; 69(2):151-5. PubMed ID: 25627335
[No Abstract] [Full Text] [Related]
4. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
[TBL] [Abstract][Full Text] [Related]
6. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L
J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
[TBL] [Abstract][Full Text] [Related]
7. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C
Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.
Atsou K; Ereshefsky L; Brignone M; Danchenko N; Diamand F; Mucha L; Touya M; Becker R; François C
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):29-42. PubMed ID: 33307885
[No Abstract] [Full Text] [Related]
9. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T; Ikuta T; Sakuma K; Okuya M; Hatano M; Matsuda Y; Iwata N
Mol Psychiatry; 2023 Jan; 28(1):402-409. PubMed ID: 36253442
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis.
Furukawa TA; Salanti G; Atkinson LZ; Leucht S; Ruhe HG; Turner EH; Chaimani A; Ogawa Y; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Suganuma A; Watanabe N; Stockton S; Geddes JR; Cipriani A
BMJ Open; 2016 Jul; 6(7):e010919. PubMed ID: 27401359
[TBL] [Abstract][Full Text] [Related]
11. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling.
Zimmerman M; Clark HL; Multach MD; Walsh E; Rosenstein LK; Gazarian D
J Affect Disord; 2016 Jan; 190():357-361. PubMed ID: 26546771
[TBL] [Abstract][Full Text] [Related]
12. Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.
Juul S; Siddiqui F; Barbateskovic M; Jørgensen CK; Hengartner MP; Kirsch I; Gluud C; Jakobsen JC
Syst Rev; 2021 May; 10(1):154. PubMed ID: 34034811
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of major depression in late life: what is the role of new agents?
Patel K; Abdool PS; Rajji TK; Mulsant BH
Expert Opin Pharmacother; 2017 Apr; 18(6):599-609. PubMed ID: 28317392
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
Meeker AS; Herink MC; Haxby DG; Hartung DM
Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839
[TBL] [Abstract][Full Text] [Related]
15. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.
Gartlehner G; Gaynes BN; Hansen RA; Thieda P; DeVeaugh-Geiss A; Krebs EE; Moore CG; Morgan L; Lohr KN
Ann Intern Med; 2008 Nov; 149(10):734-50. PubMed ID: 19017592
[TBL] [Abstract][Full Text] [Related]
16. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
Li G; Wang X; Ma D
Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.
Nussbaumer B; Morgan LC; Reichenpfader U; Greenblatt A; Hansen RA; Van Noord M; Lux L; Gaynes BN; Gartlehner G
CNS Drugs; 2014 Aug; 28(8):699-712. PubMed ID: 24794101
[TBL] [Abstract][Full Text] [Related]
19. The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews.
Monden R; Roest AM; van Ravenzwaaij D; Wagenmakers EJ; Morey R; Wardenaar KJ; de Jonge P
J Affect Disord; 2018 Aug; 235():393-398. PubMed ID: 29677603
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
